[go: up one dir, main page]

DK0542949T3 - Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner - Google Patents

Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner

Info

Publication number
DK0542949T3
DK0542949T3 DK92910019T DK92910019T DK0542949T3 DK 0542949 T3 DK0542949 T3 DK 0542949T3 DK 92910019 T DK92910019 T DK 92910019T DK 92910019 T DK92910019 T DK 92910019T DK 0542949 T3 DK0542949 T3 DK 0542949T3
Authority
DK
Denmark
Prior art keywords
hepatitis
havs
relates
virus
vaccines
Prior art date
Application number
DK92910019T
Other languages
Danish (da)
English (en)
Inventor
Ck Reinhard Gl
Stefan Brantschen
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of DK0542949T3 publication Critical patent/DK0542949T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1009—Picornaviridae, e.g. hepatitis A virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92910019T 1991-05-08 1992-05-08 Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner DK0542949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP91107526 1991-05-08
PCT/EP1992/001013 WO1992019268A1 (en) 1991-05-08 1992-05-08 New hepatitis a virus strain, method for the isolation of new hepatitis a virus strains and hepatitis a vaccines

Publications (1)

Publication Number Publication Date
DK0542949T3 true DK0542949T3 (da) 1998-12-07

Family

ID=8206711

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92910019T DK0542949T3 (da) 1991-05-08 1992-05-08 Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner

Country Status (10)

Country Link
EP (1) EP0542949B1 (de)
JP (1) JP3527238B2 (de)
AT (1) ATE163548T1 (de)
AU (1) AU662528B2 (de)
CA (1) CA2086832C (de)
DE (2) DE542949T1 (de)
DK (1) DK0542949T3 (de)
ES (1) ES2056780T3 (de)
GR (2) GR930300089T1 (de)
WO (1) WO1992019268A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3523646B2 (ja) 1992-09-18 2004-04-26 スミスクライン・ビーチヤム・バイオロジカルズ・エス・エイ Ａ型肝炎ワクチン
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
EP1802746B1 (de) 2004-10-27 2011-05-04 Crucell Switzerland AG Virosomenpartikel mit antigenen aus influenzavirus und hepatitis-b-virus
CN116514965B (zh) * 2023-06-15 2023-11-10 上海精翰生物科技有限公司 甲型肝炎病毒抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) * 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
CA1164799A (en) * 1979-09-04 1984-04-03 Paula A. Giesa Cell culture of hepatitis a virus

Also Published As

Publication number Publication date
JPH06500238A (ja) 1994-01-13
EP0542949A1 (de) 1993-05-26
AU662528B2 (en) 1995-09-07
ATE163548T1 (de) 1998-03-15
CA2086832A1 (en) 1992-11-09
DE542949T1 (de) 1993-09-02
ES2056780T1 (es) 1994-10-16
EP0542949B1 (de) 1998-03-04
GR3026612T3 (en) 1998-07-31
AU1743692A (en) 1992-12-21
JP3527238B2 (ja) 2004-05-17
GR930300089T1 (en) 1993-09-30
CA2086832C (en) 2007-05-01
DE69224590T2 (de) 1998-10-15
ES2056780T3 (es) 1998-08-16
WO1992019268A1 (en) 1992-11-12
DE69224590D1 (de) 1998-04-09

Similar Documents

Publication Publication Date Title
DK0677533T3 (da) Antistoffer mod epitoper med homologi til selv-antigener, fremgangsmåder til fremstilling og anvendelser deraf
DK0589004T3 (da) Fremgangsmåde til bestemmelse af peptider, som hører til immunologisk vigtige epitoper af HCV
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK158743C (da) Fremgangsmaade til fremstilling af et levende, svaekket hepatitis a virus og diagnostisk praeparat opnaaet ved fremgangsmaaden
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
NO20061203L (no) Fremgangsmate og sammensetning for rekontormering av multiepitopiske antigener for a initiere en immunrespons
NO169844C (no) Htlv-iii (env)-peptider
DK0649537T4 (da) Immunoassays til anti-HCV-antistoffer, ved anvendelse af antigener med konformationelle epitoper
FI942369A0 (fi) Hepatitis-C-virustesti
NO872581L (no) Et produksjon av antistoffer ved anvendelse av insolubil iserte immunkomplekser.
ES8404186A1 (es) "un procedimiento para obtener al menos un polipeptido que presenta la antigenicidad de los antigenos e del virus de la hepatitis b".
Weiland et al. Development of monoclonal neutralizing antibodies against bovine viral diarrhea virus after pretreatment of mice with normal bovine cells and cyclophosphamide
DK0701612T3 (da) Immunogent præparat af OspC-antigenvacciner til forebyggelse og behandling af Lyme sygdom og rekombinantmetode til fremsti
DK0542949T3 (da) Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner
CA2080548A1 (en) Monoclonal antibodies to hepatitis c virus
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
HK1012838A1 (en) Monoclonal antibodies to putative hcv envelope region and methods for using same
NO953749L (no) Hepatitt B-escapemutantspesifikke bindingsmolekyler
SE8601695L (sv) Fast-fasanalysmetod
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DK230485A (da) Fremgangsmaade til bestemmelse af atl virusantistof og reagens dertil
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
Brantschen Hepatitis A virus strain, method for the isolation of new hepatitis A virus strains and hepatitis A vaccines
JPS5344620A (en) Recovering of immobilized vaccine and specific antigen